Research programme: neurological injury therapeutics - PresSura Neuro

Drug Profile

Research programme: neurological injury therapeutics - PresSura Neuro

Alternative Names: EU-C-002

Latest Information Update: 07 Apr 2017

Price : $50

At a glance

  • Originator Roche
  • Developer PresSura Neuro
  • Class
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain injuries; Craniocerebral trauma; Reperfusion injury

Most Recent Events

  • 03 Apr 2017 Research programme: neurological injury therapeutics is still in preclinical development for Reperfusion-injury (Prevention, followed by stroke), Craniocerebral-trauma and Brain injuries in Australia (PresSura Neuro website, April 2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Craniocerebral-trauma in Australia
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Reperfusion-injury(Prevention) in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top